Yes..I believe.
The HCV model is huge. Massive revenues in HCV.
BIT225 ...part cure ...part cure ....part cure for HIV.
Only one for treating HIV in the macrophages.
Let's face it...you not curing HIV globally overnight.
Whoever is smart enough to partner with BIT will get No1 Market share.
It's collaborative.
Significant outcome means better patient outcome.Part Cure or manage HIV for the patient better.
BIT225 is the Tip of the iceberg.
Then there is Ebola, Dengue, Zika virus.
No value currently assigned to those drug candidates.
BIT has a pipeline of drug candidates.
You have read about BIT?
Let's talk HCV. Was BIT225 a complete failure treating HCV?
DYOR...
...and the winner is......
Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-553
-
- There are more pages in this discussion • 486 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $7.664K | 403.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1202498 | 5 |
View Market Depth
| Last trade - 13.42pm 27/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |